Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 199 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Benign Prostatic Hyperplasia (BPH) Clear all

Conditions: BPH, Benign Prostatic Hyperplasia
Interventions: SOLTIVE Thulium Laser, Standard of Care (Holmium Laser); Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Prostatic Hyperplasia
Interventions: FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Enlarged Prostate (BPH), Enlarged Prostate With Lower Urinary Tract Symptoms
Interventions: Ejaculatory-sparing (ES-sparing) HoLEP; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Benign Prostatic Hyperplasia
Interventions: Tranexamic Acid (IV), Placebo; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 45 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Enlarged Prostate (BPH), Benign Prostatic Hyperplasia
Interventions: Magneto 150 holmium laser, Moses 2.0 holmium laser; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Interventions: MCS-2; Drug
Lead sponsor: Health Ever Bio-Tech Co., Ltd.; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 40 Years and older
Enrollment: 15,240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Benign Prostatic Hyperplasia
Interventions: Optilume BPH Catheter System, Optilume Sham Device; Device
Lead sponsor: Urotronic Inc.; Industry
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 19
States / cities: Little Rock, Arkansas • Golden, Colorado • Daytona Beach, Florida + 14 more

Conditions: Benign Prostatic Hyperplasia
Interventions: UroLift® System; Device
Lead sponsor: NeoTract, Inc.; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 7
States / cities: San Diego, California • Daytona Beach, Florida • St. Petersburg, Florida + 4 more

Conditions: Prostatic Cancer, Prostatic Neoplams, Prostatic Hyperplasia, Prostate Cancer, Cancer Of Prostate
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2033
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Interventions: Alfuzosin (SL770499); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 55 Years and older · Male only
Enrollment: 1,522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 35
States / cities: Huntsville, Alabama • La Mesa, California • San Bernardino, California + 32 more

Conditions: Benign Prostatic Hyperplasia (BPH)
Interventions: Prostate Artery Embolization; Device
Lead sponsor: Northwestern University; Other
Eligibility: 45 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Benign Prostatic Hyperplasia
Interventions: S-equol, Placebo; Drug
Lead sponsor: Ausio Pharmaceuticals, LLC; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 5
States / cities: Huntsville, Alabama • Aventura, Florida • Clearwater, Florida + 2 more

Conditions: Hormone Refractory Prostate Cancer
Interventions: Docetaxel, TroVax; Drug
Lead sponsor: Oxford BioMedica; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 7
States / cities: San Bernardino, California • Stanford, California • Chicago, Illinois + 4 more

Conditions: Kidney Calculi, Urologic Diseases, Benign Prostatic Hypertrophy
Interventions: Tranexamic acid; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years · Male only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostatic Hyperplasia
Interventions: GI198745; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Benign Prostatic Hyperplasia With Outflow Obstruction, Urinary Retention, Lower Urinary Tract Symptoms
Interventions: Preoperative pelvic floor physical therapy; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Benign Prostatic Hyperplasia
Interventions: Holmium Laser Prostate Surgery; Procedure
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Benign Prostatic Hyperplasia (BPH)
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions: Prostate artery embolization; Device
Lead sponsor: Merit Medical Systems, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 8
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 4 more

Conditions: Benign Prostatic Hyperplasia
Interventions: talaporfin sodium, Saline, Drug Activator 100 J/cm, Drug Activator 200 J/cm; Drug · Device
Lead sponsor: Light Sciences Oncology; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 41
States / cities: Anniston, Alabama • Huntsville, Alabama • Anchorage, Alaska + 37 more

Conditions: BPH, Erectile Dysfunction
Interventions: Alfuzosin 10 mg; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 45 Years to 75 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Treatment of Benign Prostatic Hyperplasia
Interventions: Lumenis Pulse P120H and Xpeeda side firing fiber; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Benign Prostatic Hyperplasia (BPH)
Interventions: Prostate Artery Embolization; Device
Lead sponsor: Northwestern University; Other
Eligibility: 45 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

SOLTIVE™ Laser Enucleation for Treatment of Benign Prostatic Hyperplasia

Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects

Ejaculatory-Sparing HoLEP vs Standard HoLEP

Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation

Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)

Impact of COVID-19 on GU Disease

Optilume™ BPH Catheter System in Men With Symptomatic BPH

UroLift System TOlerability and ReCovery When Administering Local Anesthesia

Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer

Clinical Trial in Males With BPH (Enlarged Prostate)

Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)

Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)

A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.

Preoperative Pelvic Floor Physical Therapy to Minimize Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate

Duration of Medication Therapy and Outcomes After Holmium Laser Prostate Surgery for Patients With Benign Prostatic Hyperplasia (BPH)

The FLOW Registry.

Embosphere® PROstate Post Market Study

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)

Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH

Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres